Company intelligence / Profile preview

TRIM-BioTech

Hong Kong, Hong Kong

Ownership: Private
Development stage: Other

Overview

TRIM-BioTech is a Hong Kong-based biotechnology company specializing in the development of novel small molecule therapeutics that target the Tripartite Motif (TRIM) family of proteins. Spun off from the University of Hong Kong, the company leverages a proprietary drug discovery platform to identify inhibitors for proteins like TRIM28, which plays a critical role in cancer progression and viral replication. Their lead programs focus on treating hepatocellular carcinoma and managing viral infections such as HIV and COVID-19. By modulating the E3 ubiquitin ligase activity and scaffolding functions of TRIM proteins, TRIM-BioTech aims to address significant unmet needs in oncology and infectious diseases.

Therapeutic areas: Infectious DiseasesOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of Hong Kong

Beyond the preview

Go deeper on TRIM-BioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRIM-BioTech.

Explore the full profile